Precision oncology, which matches cancer treatment to a patient's genetics, is creating new opportunities for Indian healthcare firms. As cancer cases increase, Metropolis Healthcare and Syngene International are building dedicated infrastructure. Investors are tracking how these companies balance growth costs with profit margins in this specialized segment.
What Happened
Precision oncology represents a shift in cancer care from general treatment to therapies based on a patient's genetic profile. As India deals with rising cancer rates—estimated by the Indian Council of Medical Research (ICMR) at 15.6 lakh new cases annually—the demand for highly specific diagnostic tests and targeted drugs is increasing. This creates a dual opportunity: diagnostic chains need to provide the tests, and research organizations need to help develop the drugs. Both Metropolis Healthcare and Syngene International are investing heavily to capture this shift.
Metropolis Healthcare: Building The Diagnostic Network
Metropolis Healthcare is focused on capturing the diagnostic side of this trend. A major step was its acquisition of Core Diagnostics in December 2024 for ₹246.8 crore. This move was strategic, designed to pull the company into the high-complexity testing segment.
The impact is visible in the company's financial structure, where oncology testing's contribution to total revenue has grown from 4% to approximately 10%. However, the company faces a specific operational challenge: improving the profitability of this acquired business. The goal is to move the EBITDA margins of the Core Diagnostics unit from a negative 2% to over 20%. The company’s recent performance shows revenue growth of 24% in FY26, reaching ₹1,646 crore, with a 31% rise in net profit to ₹191 crore, though the stock currently trades at a P/E ratio of around 58, which suggests high expectations for future growth.
Syngene International: The R&D And Manufacturing Partner
Syngene International operates in the research and development side of precision oncology. As a CRDMO (Contract Research, Development, and Manufacturing Organization), it helps global pharmaceutical companies develop targeted therapies.
The company is expanding its focus into antibody-drug conjugates (ADCs) and biologics, with a new laboratory commissioned in Q4FY26. While the business model is strong, it is also sensitive to the R&D budgets of large global pharmaceutical clients. In FY26, Syngene experienced margin pressure, with EBITDA margins dipping to 25%. This was partly linked to inventory adjustments by a major customer, highlighting how external factors can influence the company's profitability. The market currently values the company at a trailing P/E of 46.9, reflecting confidence in its ability to navigate these short-term adjustments.
Business Realities And Risks
While the growth potential in precision oncology is clear, both companies face distinct risks. For Metropolis, the primary challenge is integration risk. Successfully merging a specialized, high-complexity diagnostic business into a mass-market diagnostic network requires tight operational control. If the company fails to lift margins at Core Diagnostics as planned, it could impact overall profitability.
For Syngene, the risk is tied to client reliance and global R&D spending. The recent inventory adjustment by a customer serves as a reminder that the company’s revenue depends on the success and spending priorities of its partners. Any slowdown in global pharmaceutical R&D, or delays in commercializing new therapies, could impact its growth trajectory.
What Investors Should Track
Investors may watch for a few specific metrics in the coming quarters. For Metropolis, the key monitorable is the margin improvement in the oncology diagnostic unit—specifically, whether they are on track to reach the 20% EBITDA target. For Syngene, the focus will be on maintaining stable relationships with major global clients and tracking the utilization of its new ADC discovery laboratory. Finally, for both firms, monitoring the broader trend of cancer diagnostic adoption in India will be essential to see if the market growth matches the high valuations currently priced into the stocks.